CalciMedica (NASDAQ:CALC) Releases Earnings Results, Beats Expectations By $0.97 EPS

CalciMedica (NASDAQ:CALC) issued its earnings results on Tuesday, August 11th. The company reported ($0.45) EPS for the quarter, beating analysts’ consensus estimates of ($1.42) by $0.97, Zacks reports.

CalciMedica Stock Performance

NASDAQ CALC opened at $2.00 on Wednesday. CalciMedica has a 1-year low of $2.00 and a 1-year high of $36.00. The company has a 50 day moving average of $3.67 and a 200-day moving average of $3.49. The company has a current ratio of 5.58, a quick ratio of 5.58 and a debt-to-equity ratio of 1.67. The firm has a market cap of $13.66 million, a price-to-earnings ratio of -0.29 and a beta of 0.91.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on CALC shares. UBS Group reissued a “neutral” rating on shares of CalciMedica in a report on Thursday, August 13th. Guggenheim started coverage on shares of CalciMedica in a research note on Thursday, August 20th. They issued a “buy” rating on the stock. Weiss Ratings raised CalciMedica from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 27th. Wall Street Zen raised CalciMedica to a “sell” rating in a report on Saturday, August 22nd. Finally, HC Wainwright reaffirmed a “neutral” rating on shares of CalciMedica in a research note on Wednesday, July 29th. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, CalciMedica presently has an average rating of “Hold” and a consensus price target of $50.00.

Insider Activity at CalciMedica

In other CalciMedica news, Director Fred A. Middleton bought 49,794 shares of CalciMedica stock in a transaction dated Thursday, June 25th. The shares were acquired at an average cost of $4.00 per share, with a total value of $199,176.00. Following the acquisition, the director directly owned 212,654 shares of the company’s stock, valued at $850,616. The trade was a 30.57% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 28.25% of the stock is owned by insiders.

Hedge Funds Weigh In On CalciMedica

Institutional investors have recently bought and sold shares of the business. Boothbay Fund Management LLC bought a new stake in shares of CalciMedica during the fourth quarter worth $506,000. Jane Street Group LLC acquired a new stake in shares of CalciMedica in the fourth quarter valued at $127,000. Renaissance Technologies LLC raised its holdings in shares of CalciMedica by 26.1% in the fourth quarter. Renaissance Technologies LLC now owns 88,300 shares of the company’s stock valued at $582,000 after buying an additional 18,300 shares during the last quarter. Cetera Investment Advisers raised its holdings in shares of CalciMedica by 33.1% in the second quarter. Cetera Investment Advisers now owns 36,385 shares of the company’s stock valued at $58,000 after buying an additional 9,045 shares during the last quarter. Finally, Envestnet Asset Management Inc. lifted its position in CalciMedica by 58.2% during the 2nd quarter. Envestnet Asset Management Inc. now owns 93,433 shares of the company’s stock worth $149,000 after buying an additional 34,386 shares in the last quarter.

About CalciMedica

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.